What is APRE (APRE) stock price today?

APRE (APRE) is currently trading at $0.62, down 1.16% today.

What is APRE P/E ratio?

APRE's P/E ratio is -0.47. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is APRE return on equity (ROE)?

APRE's return on equity (ROE) is -108.33%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is APRE's market cap?

APRE has a market capitalization of $4.06M.

NASDAQ · Biotechnology

APRE (APRE) Stock

$0.62 -1.16% NASDAQ: APRE Healthcare

Valuation

Metric	Value
Price	$0.62
Market Cap	$4.06M
P/E Ratio	-0.47
P/B Ratio	0.49
P/S Ratio	51.14
EPS (TTM)	$0.00
52-Week High	$2.22
52-Week Low	$0.55
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-108.33%
ROA	-81.25%
ROCE	-100.00%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	-101.22%
Debt/Equity	0.00
Current Ratio	5.33

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$1.0M	$2.0M	$0
Operating Profit	$-37.0M	$-113.0M	$-15.0M	$-14.0M	$-13.0M
Net Profit	$-37.0M	$-113.0M	$-14.0M	$-13.0M	$-13.0M
EPS	$-34.88	$-1359.79	$-3.95	$-2.35	$-1.93
Op Margin	—	—	-2652.8%	-953.0%	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$57.0M	$30.0M	$23.0M	$24.0M	$16.0M
Total Liabilities	$7.0M	$5.0M	$4.0M	$5.0M	$3.0M
Cash	$53.0M	$29.0M	$22.0M	$23.0M	$15.0M
Borrowings	$0	$0	$0	$0	$0

Latest News

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors GlobeNewswire · Jun 1, 2026 Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update GlobeNewswire · May 13, 2026 Oracle upgraded, Planet Fitness downgraded: Wall Street's top analyst calls The Fly · May 7, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-38.0M	$-25.0M	$-12.0M	$-14.0M	$-13.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$0	$0	$-1.0M	$-1.0M	$0
Net Cash Flow	$-36.0M	$-24.0M	$-7.0M	$1.0M	$-8.0M
Free Cash Flow	$-38.0M	$-25.0M	$-12.0M	$-14.0M	$-13.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-202.28%
Quick Ratio	8.92
Interest Coverage	—
Return 1Y	-57.19%
Return 3Y	-77.71%
Return 5Y	-99.31%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACXP	$1.40	-1.40%	-0.36	$2.22M	0.00%
ADIL	$3.33	+1.22%	-1.14	$3.20M	0.00%
APVO	$4.21	-4.10%	-0.06	$9.21M	0.00%
BCDABioCardia, Inc.	$0.84	-1.11%	-0.83	$4.88M	0.00%
CELZ	$0.79	-2.09%	-1.47	$2.05M	0.00%

About APRE

APRE is led by CEO Oren Gilad, employs 8 people, headquartered in US, publicly traded since 2019.

APRE stock trades at $0.62 with a market capitalization of $4.06M. The stock is valued at a price-to-earnings (P/E) ratio of -0.47, price-to-book of 0.49, price-to-sales of 51.14. Over the past 52 weeks the stock has ranged between $0.55 and $2.22, and currently trades 72.1% below its 52-week high.

On profitability, APRE generates a return on equity (ROE) of -108.33%, return on capital employed of -100.00%, an operating margin of 0.00%, a net profit margin of -101.22%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides